BioVision sells subsidiary to Nextech Venture

ImVision focuses on the development of novel immunotherapeutics based on its proprietary MAT (Modular-Antigen-Transport) technology to treat allergic diseases, chronic infectious diseases and possibly cancer.

The technology, developed by BioVision with its partner, the Swiss Institute of Allergy and Asthma Research (SIAF), promotes improved antigen presentation within the immune system. The company’s lead product, IVN201, an immunotherapeutic to treat cat dander allergy is currently undergoing late preclinical development and is expected to enter clinical trials early 2006.

Nextech Venture has welcomed the purchase as a means developing further innovative drugs and reaping profits in return.

Nextech’s CEO and founding partner, Dr Alfred Scheidegger said of the aquisition: “It will be ImVision’s challenge to fully exploit the potential of MAT – developing a portfolio of innovative drugs that cannot only change the way we treat allergy but even the way we immunize. If MAT works, we will see the next blockbuster here!”